Merck's acquisition of Sigma-Aldrich close to completion
Twelve months after pharmaceutical company Merck announced its intention to buy US life science company Sigma-Aldrich, steady progress has been made towards closing the deal.
On 22 September 2014, Merck revealed its agreement with Sigma-Aldrich to purchase the latter for US$17 billion — US$140 cash per share — establishing itself as one of the leading players in the US$130 billion global life science industry. The merged company will be led by Merck Millipore CEO Udit Batra.
On 11 August 2015, Sigma-Aldrich and Merck announced they had obtained all necessary antitrust approvals, with the approval of the European Commission (EC) being conditional upon the sale of parts of Sigma-Aldrich’s solvents and inorganics business in Europe. Negotiations with potential buyers are now in the final stage.
Once a binding agreement has been signed, the EC must approve the buyer before Merck can complete the Sigma-Aldrich acquisition. Completion is expected within the next two months.
Suspicious citation numbers found in high-impact journals
The likely manipulation of citation numbers by research paper mills in high-impact cancer...
TGA developing reforms to strengthen sunscreen regulation
Brands would be required to test the SPF of their finished product, rather than just the base...
2026 Nobel Prize winners announced
It's that time of year again — the first of the 2026 Nobel Prizes have been announced.
